Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.-论文-万方医学网

作者： Victoria,Klepsch ^[1] ; Natascha,Hermann-Kleiter ^[1] ; Patricia,Do-Dinh ^[1] ; Bojana,Jakic ^[1] ; Anne,Offermann ^[2] ; Mirjana,Efremova ^[3] ; Sieghart,Sopper ^[4] ; Dietmar,Rieder ^[3] ; Anne,Krogsdam ^[3] ; Gabriele,Gamerith ^[4] ; Sven,Perner ^[2] ; Alexandar,Tzankov ^[5] ; Zlatko,Trajanoski ^[4] ; Dominik,Wolf ^[4] ; Gottfried,Baier ^[6]

作者单位： Division of Translational Cell Genetics, Medical University of Innsbruck, 6020, Innsbruck, Austria. ^[1] Pathology of the University Hospital Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Lung Center, 23538, Leubeck, Germany. ^[2] Biocenter, Division of Bioinformatics, Medical University of Innsbruck, 6030, Innsbruck, Austria. ^[3] Tumor Immunology, Tyrolean Cancer Institute & Internal Medicine V, 6020, Innsbruck, Austria. ^[4] Department of Pathology, University of Basel, University Hospital Basel, 4031, Basel, Switzerland. ^[5] Medical Clinic III, Oncology, Hematology & Rheumatology, University Clinic Bonn, 53127, Bonn, Germany. ^[6] Division of Translational Cell Genetics, Medical University of Innsbruck, 6020, Innsbruck, Austria. gottfried.baier@i-med.ac.at. ^[7]

主题词动物(Animals);活组织检查(Biopsy);COUP转录因子类(COUP Transcription Factors);疾病恶化(Disease Progression);女(雌)性(Female);基因沉默(Gene Silencing);杂合子(Heterozygote);人类(Humans);免疫系统(Immune System);男(雄)性(Male);小鼠(Mice);小鼠, 近交C57BL(Mice, Inbred C57BL);肿瘤移植(Neoplasm Transplantation);肿瘤(Neoplasms);RNA, 小分子干扰(RNA, Small Interfering);受体, 类固醇(Receptors, Steroid);阻遏蛋白质类(Repressor Proteins);脾(Spleen);T淋巴细胞(T-Lymphocytes);增量调节(Up-Regulation)

DOI 10.1038/s41467-018-04004-2

PMID 29670099

发布时间 2021-10-28

检索历史清除

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.

Nature communications

相似文献

Nature communications

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.

Nature communications

相似文献

Nature communications

相关期刊

检索历史清除